Semaglutide and Heart Health: What the Clinical Evidence Actually Shows

You've seen the headlines, here's what the trial actually found

Picture someone in their fifties who's had a heart attack, carries a BMI above 30, and doesn't have type 2 diabetes. They're already on statins and antihypertensives. Their cardiologist mentions semaglutide, and they go home wondering whether this is a genuine treatment option or pharmaceutical optimism. The SELECT trial was designed precisely for that person.

SELECT enrolled 17,604 adults across that profile (existing cardiovascular disease, obesity, no diabetes) and followed them for a median of around five years. Those taking weekly semaglutide 2.4mg saw a 20% relative reduction in a composite of major adverse cardiovascular events: non-fatal heart attack, non-fatal stroke, and death from cardiovascular causes. That result was statistically significant and consistent across subgroups. You can read the full trial data in the New England Journal of Medicine's semaglutide trial paper.

On the back of SELECT, the MHRA granted semaglutide a second UK licence covering exactly this cardiovascular indication. It is not the same as the weight-loss licence, and it is not a claim extrapolated from weight loss. The drug was shown to reduce heart events, and the regulator recognised that. If you want a fuller picture of how Wegovy supports heart health mechanically, that detail is worth reading alongside this.

Why semaglutide might help the heart beyond just losing weight

One of the more striking findings from SELECT was that the cardiovascular benefit appeared within the first year, before substantial weight loss had accumulated. That timing prompted researchers to ask whether something else is happening beyond simply carrying fewer kilograms.

Several mechanisms are under active investigation. Semaglutide reduces inflammation markers like CRP and affects how the body handles blood pressure, triglycerides and blood glucose, all risk factors for cardiovascular disease independently of body weight. GLP-1 receptors exist in cardiac tissue, and there is preliminary evidence of direct anti-inflammatory effects on arterial walls. None of this is fully settled science, but it shifts the picture from "weight loss that incidentally helps the heart" to something more targeted. The specific cardiovascular benefits of Wegovy in clinical evidence are worth reviewing if you're weighing this as part of a broader health conversation with your doctor.

What this means practically: if your concern is heart health rather than (or alongside) weight, that conversation with a prescriber becomes even more important. Semaglutide is not a substitute for established cardiovascular medicines, and it doesn't replace lifestyle changes. It sits alongside them.

A quick habit worth forming: if you're already on heart medicines, note them all before your consultation. A prescriber reviewing your case will want the full picture, and having that list ready takes under a minute.

Who can access semaglutide for cardiovascular reasons, and how

The cardiovascular licence covers adults with established cardiovascular disease (a prior heart attack, stroke, or peripheral arterial disease, among other qualifying events) and a BMI of 30 or above. It is separate from the weight-management licence, the Wegovy overview sets out how both indications sit within the licensed profile. The age eligibility and exact qualifying criteria are assessed by a prescriber; BMI alone is not the determining factor.

On the NHS, access to Wegovy for either indication runs through specialist weight management services under NICE's guidance, and waiting lists vary considerably. The NHS England guidance on weight management injections outlines how that route works, including the wraparound dietary support that goes with it.

For those who want to be seen more promptly, a regulated private clinic is the alternative. At our pharmacy, every consultation is read personally by a GPhC-registered Independent Prescriber (the same day) and eligibility is assessed properly, not rubber-stamped. If you're unsure whether your cardiac history makes you a candidate, checking your eligibility through a free consultation is the place to start. If cost is a factor in your thinking, the Wegovy pricing context page sets out what private treatment typically involves.

Side effects, cautions, and what to watch for

The most common side effects with semaglutide are gastrointestinal: nausea, loose stools, constipation, indigestion. These are most pronounced in the early weeks of treatment and after dose increases, and for most people they ease off considerably once the dose settles. Headache and fatigue also occur.

More serious but infrequent effects require prompt attention. On 29 January 2026, the MHRA issued a Drug Safety Update drawing attention to acute pancreatitis as a known risk with GLP-1 medicines: severe, persistent stomach pain that reaches the back (with or without vomiting) is a signal to seek medical help the same day, not to wait and see. If you want to explore the relationship between semaglutide and heart rate, that's a separate but relevant area: a modest resting heart-rate increase has been observed in trials, worth discussing with your prescriber if you have an arrhythmia or palpitation history.

Semaglutide is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive. Specific considerations around Wegovy and pregnancy are set out separately. Anyone under 18 is outside the licensed population for this medicine. Yellow Card reporting at the MHRA's Yellow Card scheme is how patients and prescribers can report suspected side effects in the UK, it matters for medicines still under additional monitoring.